Gaxos.ai (GXAI) expands at‑the‑market program by $1.07M
Rhea-AI Filing Summary
Gaxos.ai Inc. is supplementing its prior prospectuses to raise the size of its at-the-market program under the Sales Agreement with H.C. Wainwright & Co. The company is offering up to an additional $1,065,001 of its common stock pursuant to the Sales Agreement.
The supplement states the Sales Agreement previously produced gross proceeds of approximately $5,600,000 from 3,096,481 shares sold. It reports 10,219,934 shares outstanding and 9,997,502 shares held by non-affiliates as of the prospectus supplement, with a disclosed public float market value of $19,995,004 using a $2.00 per-share price on February 3, 2026. The Company notes compliance with General Instruction I.B.6 of Form S-3.
Positive
- None.
Negative
- None.
Insights
ATM increase adds modest incremental raising capacity.
The supplement increases the at-the-market capacity by $1,065,001, adding to prior sales of $5,600,000 under the Sales Agreement with H.C. Wainwright. This is an administrative update that preserves the issuer's option to sell additional shares into the market.
Cash-flow treatment is issuer proceeds; the timing and pace of any sales are governed by the Sales Agreement and market conditions. Public-float calculations reference 10,219,934 shares outstanding and a $19,995,004 public float using a $2.00 per-share price on February 3, 2026.
Supplemental prospectus follows Form S-3 instruction limits.
The filing expressly cites General Instruction I.B.6 of Form S-3 and states the company has sold approximately $5,600,000 of securities in the prior 12-calendar-month period, qualifying it to register up to an additional $1,065,001. The prospectus supplement reiterates customary disclosure language about SEC non-approval.
Key qualifier: the offer is made "pursuant to" the Sales Agreement; any sale activity and timing remain subject to that agreement and market conditions. Subsequent filings will disclose actual sale quantities and proceeds when shares are sold under the program.
FAQ
What amount is Gaxos.ai (GXAI) registering under this prospectus supplement?
How much has Gaxos.ai already sold under the Sales Agreement?
Who is acting as sales agent for the ATM program?
What are Gaxos.ai's shares outstanding and public float figures cited?
Does this supplement change how proceeds will be treated?